Laboratory Medicine ›› 2022, Vol. 37 ›› Issue (5): 443-446.DOI: 10.3969/j.issn.1673-8640.2022.05.009
• Original article • Previous Articles Next Articles
HUANG Wanhong1, MO Lida2, LUO Xiaolu2, LIN Yinghui1, LIU Zeduan2, CHEN Songlin1()
Received:
2021-04-01
Revised:
2021-05-17
Online:
2022-05-30
Published:
2022-07-20
Contact:
CHEN Songlin
HUANG Wanhong, MO Lida, LUO Xiaolu, LIN Yinghui, LIU Zeduan, CHEN Songlin. Level changes of GM and BG in patients with IPA before and after treatment in different immune states[J]. Laboratory Medicine, 2022, 37(5): 443-446.
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.shjyyx.com/EN/10.3969/j.issn.1673-8640.2022.05.009
项目 | GM/ (µg/L) | BG/ (pg/mL) | CD3+ T细胞/ (个/μL) | CD4+ T细胞/ (个/μL) | CD8+ T细胞/ (个/μL) | CD4/CD8 比值 |
---|---|---|---|---|---|---|
治疗前 | 1.01 (0.30~1.73)* | 79.30 (24.00~401.20)* | 544 (368~1 158) | 181 (57~392) | 373 (199~635) | 0.35 (0.12~1.38) |
治疗1个月 | 0.87 (0.54~1.10)* | 78.4 (21.80~250.80)* | 652 (469~1 171) | 272 (106~465) | 402 (240~702) | 0.57 (0.23~1.13) |
治疗3个月 | 0.45 (0.26~0.78) | 28.75 (14.30~116.80) | 829 (544~1 238) | 271 (104~611) | 405 (267~729) | 0.56 (0.23~1.52) |
H值 | 17.052 | 8.129 | 3.756 | 4.859 | 1.613 | 1.673 |
P值 | 0.000 | 0.017 | 0.153 | 0.08 | 0.446 | 0.433 |
项目 | GM/ (µg/L) | BG/ (pg/mL) | CD3+ T细胞/ (个/μL) | CD4+ T细胞/ (个/μL) | CD8+ T细胞/ (个/μL) | CD4/CD8 比值 |
---|---|---|---|---|---|---|
治疗前 | 1.01 (0.30~1.73)* | 79.30 (24.00~401.20)* | 544 (368~1 158) | 181 (57~392) | 373 (199~635) | 0.35 (0.12~1.38) |
治疗1个月 | 0.87 (0.54~1.10)* | 78.4 (21.80~250.80)* | 652 (469~1 171) | 272 (106~465) | 402 (240~702) | 0.57 (0.23~1.13) |
治疗3个月 | 0.45 (0.26~0.78) | 28.75 (14.30~116.80) | 829 (544~1 238) | 271 (104~611) | 405 (267~729) | 0.56 (0.23~1.52) |
H值 | 17.052 | 8.129 | 3.756 | 4.859 | 1.613 | 1.673 |
P值 | 0.000 | 0.017 | 0.153 | 0.08 | 0.446 | 0.433 |
组别 | 例数 | GM/ (µg/L) | BG/(pg/mL) | CD3+ T细胞/ (个/μL) | CD4+ T细胞/ (个/μL) | CD8+ T细胞/ (个/μL) | CD4/CD8 比值 |
---|---|---|---|---|---|---|---|
HIV组 | 40 | ||||||
治疗前 | 1.02 (0.28~1.70)* | 71.65(22.05~407.95)* | 492 (312~1 057) | 85 (22~195) | 401 (224~768) | 0.20(0.07~0.36) | |
治疗1个月 | 0.88 (0.48~1.13)* | 79.85 (21.95~294.08) * | 596 (328~858) | 139 (80~274) | 361 (217~643) | 0.31(0.21~0.68) | |
治疗3个月 | 0.50 (0.26~0.88) | 25.30 (15.10~103.33) | 636 (362~1 080) | 129 (68~217) | 418 (237~805) | 0.33(0.14~0.56) | |
H值 | 9.372 | 7.184 | 0.885 | 4.594 | 0.237 | 7.856 | |
P值 | 0.009 | 0.028 | 0.642 | 0.101 | 0.888 | 0.020 | |
非HIV组 | 23 | ||||||
治疗前 | 0.96 (0.36~1.98)* | 127.40(26.50~351.60) | 868 (408~1 272)# | 468 (207~778)# | 311 (158~561) | 1.61(1.31~2.33)# | |
治疗1个月 | 0.86 (0.56~1.01)* | 44.34 (17.60~220.60) | 1 131 (598~1 710)# | 552 (321~721)# | 496 (253~988) | 1.21(0.76~1.64)# | |
治疗3个月 | 0.45 (0.28~0.74) | 55.40(12.10~125.13) | 1 080 (829~1 698)# | 1 080 (829~1 698)# | 376 (283~665) | 1.64(0.93~1.94)# | |
H值 | 8.676 | 1.977 | 3.488 | 3.478 | 4.977 | 1.673 | |
P值 | 0.013 | 0.372 | 0.175 | 0.176 | 0.083 | 0.433 |
组别 | 例数 | GM/ (µg/L) | BG/(pg/mL) | CD3+ T细胞/ (个/μL) | CD4+ T细胞/ (个/μL) | CD8+ T细胞/ (个/μL) | CD4/CD8 比值 |
---|---|---|---|---|---|---|---|
HIV组 | 40 | ||||||
治疗前 | 1.02 (0.28~1.70)* | 71.65(22.05~407.95)* | 492 (312~1 057) | 85 (22~195) | 401 (224~768) | 0.20(0.07~0.36) | |
治疗1个月 | 0.88 (0.48~1.13)* | 79.85 (21.95~294.08) * | 596 (328~858) | 139 (80~274) | 361 (217~643) | 0.31(0.21~0.68) | |
治疗3个月 | 0.50 (0.26~0.88) | 25.30 (15.10~103.33) | 636 (362~1 080) | 129 (68~217) | 418 (237~805) | 0.33(0.14~0.56) | |
H值 | 9.372 | 7.184 | 0.885 | 4.594 | 0.237 | 7.856 | |
P值 | 0.009 | 0.028 | 0.642 | 0.101 | 0.888 | 0.020 | |
非HIV组 | 23 | ||||||
治疗前 | 0.96 (0.36~1.98)* | 127.40(26.50~351.60) | 868 (408~1 272)# | 468 (207~778)# | 311 (158~561) | 1.61(1.31~2.33)# | |
治疗1个月 | 0.86 (0.56~1.01)* | 44.34 (17.60~220.60) | 1 131 (598~1 710)# | 552 (321~721)# | 496 (253~988) | 1.21(0.76~1.64)# | |
治疗3个月 | 0.45 (0.28~0.74) | 55.40(12.10~125.13) | 1 080 (829~1 698)# | 1 080 (829~1 698)# | 376 (283~665) | 1.64(0.93~1.94)# | |
H值 | 8.676 | 1.977 | 3.488 | 3.478 | 4.977 | 1.673 | |
P值 | 0.013 | 0.372 | 0.175 | 0.176 | 0.083 | 0.433 |
组别 | 例数 | GM/ (µg/L) | BG/ (pg/mL) | CD3+ T细胞/ (个/μL) | CD4+ T细胞/ (个/μL) | CD8+ T细胞/ (个/μL) | CD4/CD8 比值 |
---|---|---|---|---|---|---|---|
A组 | 37 | ||||||
治疗前 | 0.99 (0.29~1.57)* | 127.40(35.90~506.75)* | 399 (239~588) * | 67 (16~155) * | 324 (151~504) | 0.16 (0.07~0.30) | |
治疗1个月 | 0.87 (0.49~1.13)* | 98.20 (30.10~323.90) * | 555 (314~868) | 129 (72~261) | 319 (202~587) | 0.30 (0.20~0.70) | |
治疗3个月 | 0.41 (0.25~0.87) | 40.00 (16.75~145.80) | 657 (356~1 080) | 123 (65~274) | 431 (225~781) | 0.30 (0.12~0.62) | |
B组 | 16 | ||||||
治疗前 | 1.53 (0.44~3.35)* | 28.50(18.75~182.42) | 812 (513~1 136) | 315 (251~397) | 419 (240~753) | 0.78 (0.44~1.37) | |
治疗1个月 | 1.00 (0.82~1.54)* | 26.55 (15.25~106.20) | 853 (597~1 285) | 317 (275~522) | 391 (259~671) | 0.88 (0.58~1.27) | |
治疗3个月 | 0.52 (0.26~0.78) | 25.75(11.30~110.97) | 789 (575~1 259) | 348 (245~544) | 318 (277~663) | 0.94 (0.51~1.39) | |
C组 | 10 | ||||||
治疗前 | 0.60 (0.25~1.30)# | 37.70(11.42~452.93) | 1 418 (1 208~1 756) | 806 (620~1 128) | 530 (376~648) | 1.78 (1.40~2.32) | |
治疗1个月 | 0.78 (0.33~0.89)△ | 28.15 (10.22~232.28) | 1 727 (1 202~1 949) | 666 (526~915) | 863 (500~1 121) | 0.76 (0.55~1.73) | |
治疗3个月 | 0.48 (0.45~0.73) | 12.40(10.00~143.40) | 1 476 (1 064~1 971) | 823 (663~1 050) | 605 (370~998) | 1.82 (0.86~1.91) |
组别 | 例数 | GM/ (µg/L) | BG/ (pg/mL) | CD3+ T细胞/ (个/μL) | CD4+ T细胞/ (个/μL) | CD8+ T细胞/ (个/μL) | CD4/CD8 比值 |
---|---|---|---|---|---|---|---|
A组 | 37 | ||||||
治疗前 | 0.99 (0.29~1.57)* | 127.40(35.90~506.75)* | 399 (239~588) * | 67 (16~155) * | 324 (151~504) | 0.16 (0.07~0.30) | |
治疗1个月 | 0.87 (0.49~1.13)* | 98.20 (30.10~323.90) * | 555 (314~868) | 129 (72~261) | 319 (202~587) | 0.30 (0.20~0.70) | |
治疗3个月 | 0.41 (0.25~0.87) | 40.00 (16.75~145.80) | 657 (356~1 080) | 123 (65~274) | 431 (225~781) | 0.30 (0.12~0.62) | |
B组 | 16 | ||||||
治疗前 | 1.53 (0.44~3.35)* | 28.50(18.75~182.42) | 812 (513~1 136) | 315 (251~397) | 419 (240~753) | 0.78 (0.44~1.37) | |
治疗1个月 | 1.00 (0.82~1.54)* | 26.55 (15.25~106.20) | 853 (597~1 285) | 317 (275~522) | 391 (259~671) | 0.88 (0.58~1.27) | |
治疗3个月 | 0.52 (0.26~0.78) | 25.75(11.30~110.97) | 789 (575~1 259) | 348 (245~544) | 318 (277~663) | 0.94 (0.51~1.39) | |
C组 | 10 | ||||||
治疗前 | 0.60 (0.25~1.30)# | 37.70(11.42~452.93) | 1 418 (1 208~1 756) | 806 (620~1 128) | 530 (376~648) | 1.78 (1.40~2.32) | |
治疗1个月 | 0.78 (0.33~0.89)△ | 28.15 (10.22~232.28) | 1 727 (1 202~1 949) | 666 (526~915) | 863 (500~1 121) | 0.76 (0.55~1.73) | |
治疗3个月 | 0.48 (0.45~0.73) | 12.40(10.00~143.40) | 1 476 (1 064~1 971) | 823 (663~1 050) | 605 (370~998) | 1.82 (0.86~1.91) |
[1] | 马丽, 陈杭薇, 李雪辉, 等. 肺曲霉菌病的临床研究进展[J]. 中华医院感染学杂志, 2016, 26(16):3835-3837. |
[2] |
WORKUM J D, DE JONG S W, GRESNIGT M S, et al. Microbiological and immunological characteristics of a lethal pulmonary Aspergillus niger infection in a non-neutropenic patient[J]. Med Mycol Case Rep, 2018, 21:4-7.
DOI URL |
[3] | 廖军红, 梁红卫, 邓睿, 等. 肺泡灌洗液GM实验对免疫功能正常的侵袭性肺曲霉菌病的早期诊断价值[J]. 黑龙江医药, 2020, 33(5):1158-1160. |
[4] | 血液病/恶性肿瘤患者侵袭性真菌病的诊断标准与治疗原则(第五次修订版)[J]. 临床医学研究与实践, 2017, 2(20):201. |
[5] | 艾滋病合并侵袭性真菌病诊治专家共识[J]. 中华传染病杂志, 2019, 7(10):581-593. |
[6] | 任增花, 徐凌. 侵袭性肺曲霉菌病诊断方法的研究进展[J]. 中国临床医学, 2018, 25(6):1009-1015. |
[7] |
SHI C, SHAN Q, XIA J, et al. Incidence,risk factors and mortality of invasive pulmonary aspergillosis in patients with influenza:a systematic review and meta-analysis[J]. Mycoses, 2022, 65(2):152-163.
DOI URL |
[8] | 薛子东, 卫军, 原琛利, 等. 山西省1996—2013年HIV/AIDS病人的病死率及影响因素的研究[J]. 中国艾滋病性病, 2015, 21(8):676-679. |
[9] | 李永红, 李宏科, 王芳, 等. 慢性阻塞性肺疾病患者合并侵袭性肺曲霉菌感染危险因素的Meta分析[J]. 中国抗生素杂志, 2021, 46(2):170-176. |
[10] | 张美泉. 65例肺曲霉病患者的危险因素和临床特点研究[J]. 辽宁医学杂志, 2019, 33(1):63-67. |
[11] | 闫晓培, 孔辉, 胡松, 等. 侵袭性真菌病免疫治疗策略与研究进展[J]. 中华传染病杂志, 2015, 33(4):250-253. |
[12] | 曾淑英, 刘霆, 孟文彤, 等. 恶性血液病患者侵袭性真菌感染GM和BG抗原检测的价值[J]. 中华血液学杂志, 2011, 32(1):43-46. |
[1] | WANG Yangshuyi, YE WEI, LIN Zhihao, HUANG Yuenuo, FANG Tao, DONG Xiaoting. Construction and validation of a model for pyroptosis-related features in lung adenocarcinoma [J]. Laboratory Medicine, 2023, 38(9): 833-841. |
[2] | CHEN Danyang, ZHENG Siyu, ZHENG Ruilin, SU Jingyao, ZHU Bing, LI Yinghua. Research progress in influenza viruses [J]. Laboratory Medicine, 2023, 38(7): 696-703. |
[3] | WU Youhong, SONG Yunxiao, ZHU Yong, GE Wen, BIAN Xiaobo, YUAN Wenhua, ZHAO Zhiyun. Role of blood lipid levels in assessment of coronary artery stenosis and its treatment in patients with coronary heart disease [J]. Laboratory Medicine, 2023, 38(6): 584-589. |
[4] | REN Huirong, XU Tingjuan, WU Tao, HUANG Mei, YANG Liang. Role of serum progranulin in type Ⅰ autoimmune hepatitis prognosis evaluation [J]. Laboratory Medicine, 2023, 38(3): 245-250. |
[5] | CHEN Zhe, ZHANG Ling, LIU Jie, WANG Xia, ZHANG Bin, GAO Binghua. Relationship between serum miR-326 and chemotherapy sensitivity and prognosis in patients with treatment-related hematological malignancy [J]. Laboratory Medicine, 2023, 38(3): 251-256. |
[6] | ZHOU Ying, REN Yihui, LI Guangming. Serum miR-148a expression in children with autoimmune hepatitis and its correlation with inflammatory factors [J]. Laboratory Medicine, 2023, 38(12): 1130-1134. |
[7] | WANG Su, DING Li, JIANG Wenrong, MIAO Yingxin, ZHANG Yanmei, ZHAO Hu. Research progress on drug resistance and treatment strategies of hypervirulent Klebsiella pneumoniae [J]. Laboratory Medicine, 2023, 38(1): 81-86. |
[8] | SHANG Xipeng, LI Sha, DU Jinghui, LIU Xu. Research status of Actinotignum schaalii [J]. Laboratory Medicine, 2022, 37(4): 392-395. |
[9] | SONG Yunxiao, TONG Wei, ZHANG Haichen, ZHANG Yinwang, BIAN Xiaobo, ZHANG Linlin, YUAN Wenhua, ZHAO Zhiyun, GE Wen, YAO Tianyue. Correlation of systemic inflammatory markers and fracture occurrence in elderly patients with osteoporosis [J]. Laboratory Medicine, 2022, 37(3): 235-239. |
[10] | SHI Penghui, FAN Weiguang, ZHANG Zhen, SU Miaomiao, MENG Juan, LU Xinli. Dynamic changes and clinical significance of CXCR5,sPD-1 and Hcy in AIDS patients during therapy [J]. Laboratory Medicine, 2022, 37(2): 103-107. |
[11] | WU Wenping, XU Linjuan, WANG Jiaheng, ZHANG Nana. Correlation analysis of PBK/TOPK expression with treatment response and survival prognosis in elderly patients with acute myeloid leukemia [J]. Laboratory Medicine, 2022, 37(11): 1017-1022. |
[12] | ZHANG Yinwang, LIU Jinyu, SONG Yunxiao, GE Wen, ZHANG Linlin, YUAN Wenhua, ZHAO Zhiyun. Relationship between preoperative SII and postoperative infection in patients with open fracture after internal fixation [J]. Laboratory Medicine, 2022, 37(11): 1071-1074. |
[13] | HU Deyu, QIAN Jun, YANG Haiou, WANG Yu, LUO Jun, TANG Zhenhua. Anti-Müllerian hormone in evaluating ovarian reserve among women with autoimmune thyroid disease undergoing controlled ovulation hyper-stimulation [J]. Laboratory Medicine, 2021, 36(9): 909-913. |
[14] | YANG Keke, WU Junyuan, CAO Xingjian. Role of anti-nuclear antibody-dense fine speckled pattern for diagnosing systemic autoimmune rheumatic disease [J]. Laboratory Medicine, 2021, 36(7): 691-695. |
[15] | ZHANG Guanyi, YAO Dongting, WANG Jian, HU Xiaobo. Research progress on Chinese and western medicine treatment for Candida glabrata infection [J]. Laboratory Medicine, 2021, 36(7): 761-765. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||